Pharma BD Deal Intelligence
The $15.1B acquisition that consolidated life sciences tools into an unassailable distribution moat. Life Technologies brought Ion Torrent sequencing and Applied Biosystems' PCR franchise, giving Thermo Fisher dominance across genomics, proteomics, and cell biology workflows.
Life Technologies agreed to a $13.6 billion buyout by Thermo Fisher Scientific, creating an unrivaled leader in serving research, specialty diagnostics and…
Thermo Fisher closes $13.6B Life Tech acquisition, creating the world's largest life sciences tools company.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Thermo Fisher Scientific acquired Life Technologies Corporation for $76.13 per share in cash (approximately $13.6 billion equity value plus $1.5 billion in assumed net debt, totaling approximately $15.1 billion enterprise value). The deal created the world's leading life sciences tools company.
$15.0B Global Genomics & Life Sciences Tools (2013) · $15.1B Enterprise Value (largest tools deal ever at time)
Thermo Fisher acquired Life Technologies for $15.1B, creating the world's largest life sciences tools company. Life Technologies (formed from the 2008 merger of Invitrogen and Applied Biosystems) brought Ion Torrent NGS technology, qPCR instruments, Gibco cell culture media, and the world's largest catalog of molecular biology reagents.
The acquisition gave Thermo Fisher a dominant position in genetic analysis (Applied Biosystems), cell biology (Invitrogen/Gibco), and emerging NGS (Ion Torrent). Key competitors included Illumina (dominant in NGS), Agilent, and Bio-Rad. While Ion Torrent didn't unseat Illumina in high-throughput sequencing, it found niches in clinical/targeted sequencing. The combined company's revenue grew from ~$17B (2014) to $44B (2024).
Thermo Fisher announces acquisition to combine genomics, proteomics, and analytical instrument portfolios.
FTC clears deal conditioned on divesting siRNA reagents, cell culture media/sera to GE Healthcare.
Thermo Fisher acquires Life Technologies at $76.13/share creating Life Sciences Solutions segment.
New segment created with Mark Stevenson (ex-Life Tech COO) as president. Part of Thermo Fisher Scientific Inc.'s $15.1B deal to acquire Life Technologies Corporation.
Thermo Fisher achieves $275M adjusted operating income synergies by year 3 as planned.
Life Tech transformed Thermo Fisher into dominant genomics/proteomics platform. Synergies delivered on time.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Thermo Fisher Scientific Inc. / Life Technologies Corporation (this deal) | 2013 | $15.1B | 84 |
| Thermo Fisher Scientific Inc. / Patheon N.V. | 2017 | $7.2B | 89 |
| Thermo Fisher Scientific Inc. / PPD Inc. | 2021 | $17.4B | 77 |
| Thermo Fisher Scientific Inc. / Dionex Corporation | 2010 | $2.1B | 76 |
| Thermo Fisher Scientific Inc. / Henogen S.A. (Novasep viral vector business) | 2021 | $875M | — |
| Thermo Fisher Scientific Inc. / Brammer Bio | 2019 | $1.7B | — |
| Thermo Fisher Scientific Inc. / Clario Holdings, Inc. | 2025 | $9.4B | — |
← Browse all deals · How we score deals
More: 2013 deals · Thermo Fisher Scientific Inc. deals · Multiple (undisclosed) deals